
## Yugang Dong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3866773/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Fisetin inhibits cardiac hypertrophy by suppressing oxidative stress. Journal of Nutritional Biochemistry, 2018, 62, 221-229.	4.2	43
2	Sestrin 1 ameliorates cardiac hypertrophy <i>via</i> autophagy activation. Journal of Cellular and Molecular Medicine, 2017, 21, 1193-1205.	3.6	40
3	The association of metabolic syndrome components and chronic kidney disease in patients with hypertension. Lipids in Health and Disease, 2019, 18, 229.	3.0	35
4	Lycopene protects against pressure overload-induced cardiac hypertrophy by attenuating oxidative stress. Journal of Nutritional Biochemistry, 2019, 66, 70-78.	4.2	34
5	REDD1 attenuates cardiac hypertrophy via enhancing autophagy. Biochemical and Biophysical Research Communications, 2014, 454, 215-220.	2.1	32
6	Sestrin 2 attenuates neonatal rat cardiomyocyte hypertrophy induced by phenylephrine via inhibiting ERK1/2. Molecular and Cellular Biochemistry, 2017, 433, 113-123.	3.1	30
7	Maf1 ameliorates cardiac hypertrophy by inhibiting RNA polymerase III through ERK1/2. Theranostics, 2019, 9, 7268-7281.	10.0	27
8	Comparative Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients. Stroke, 2021, 52, 1225-1233.	2.0	26
9	Role of Exosomal miRNAs in Heart Failure. Frontiers in Cardiovascular Medicine, 2020, 7, 592412.	2.4	26
10	Efficacy and safety of antithrombotic regimens after coronary intervention in patients on oral anticoagulation: Traditional and Bayesian meta-analysis of clinical trials. International Journal of Cardiology, 2016, 205, 89-96.	1.7	25
11	AMPK blunts chronic heart failure by inhibiting autophagy. Bioscience Reports, 2018, 38, .	2.4	24
12	The cardiac translational landscape reveals that micropeptides are new players involved in cardiomyocyte hypertrophy. Molecular Therapy, 2021, 29, 2253-2267.	8.2	24
13	The critical role of Sestrin 1 in regulating the proliferation of cardiac fibroblasts. Archives of Biochemistry and Biophysics, 2014, 542, 1-6.	3.0	22
14	DJ-1 activates autophagy in the repression of cardiac hypertrophy. Archives of Biochemistry and Biophysics, 2017, 633, 124-132.	3.0	21
15	Transcribed Ultraconserved Regions, Uc.323, Ameliorates Cardiac Hypertrophy by Regulating the Transcription of CPT1b (Carnitine Palmitoyl transferase 1b). Hypertension, 2020, 75, 79-90.	2.7	20
16	Meta-analysis of metabolic syndrome and its individual components with risk of atrial fibrillation in different populations. BMC Cardiovascular Disorders, 2021, 21, 90.	1.7	19
17	Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4–5 Chronic Kidney Disease or on Dialysis. Cardiovascular Drugs and Therapy, 2021, 35, 273-281.	2.6	19
18	AMPK attenuates ventricular remodeling and dysfunction following aortic banding in mice via the Sirt3/Oxidative stress pathway. European Journal of Pharmacology, 2017, 814, 335-342.	3.5	18

#	Article	IF	CITATIONS
19	Signaling cascades in the failing heart and emerging therapeutic strategies. Signal Transduction and Targeted Therapy, 2022, 7, 134.	17.1	18
20	Prognostic Significance of Serum Cysteine-Rich Protein 61 in Patients with Acute Heart Failure. Cellular Physiology and Biochemistry, 2018, 48, 1177-1187.	1.6	16
21	Meta-analysis of type 1 diabetes mellitus and risk of cardiovascular disease. Journal of Diabetes and Its Complications, 2021, 35, 107833.	2.3	16
22	Visit-to-Visit Blood Pressure Variability and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Hypertension, 2021, 77, 1549-1558.	2.7	16
23	Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment. International Journal of Cardiology, 2016, 221, 832-836.	1.7	15
24	Overweight Without Central Obesity, Cardiovascular Risk, and All-Cause Mortality. Mayo Clinic Proceedings, 2018, 93, 709-720.	3.0	14
25	Plasma Oxidized Low-Density Lipoprotein Is an Independent Risk Factor in Young Patients with Coronary Artery Disease. Disease Markers, 2011, 31, 295-301.	1.3	14
26	Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction. Hypertension, 2022, 79, 241-250.	2.7	14
27	Prognostic Implication of Liver Function Tests in Heart Failure With Preserved Ejection Fraction Without Chronic Hepatic Diseases: Insight From TOPCAT Trial. Frontiers in Cardiovascular Medicine, 2021, 8, 618816.	2.4	13
28	Effect of physician characteristics and knowledge on the quality of dyslipidemia management and LDL–C target goal achievement in China: Subgroup analysis of the Dyslipidemia International Study. Journal of Global Health, 2017, 7, 020702.	2.7	12
29	A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. American Journal of Cardiology, 2017, 120, 569-576.	1.6	11
30	C2HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial. BMC Medicine, 2021, 19, 44.	5.5	11
31	Adaptation of endothelial cells to shear stress under atheroprone conditions by modulating internalization of vascular endothelial cadherin and vinculin. Annals of Translational Medicine, 2020, 8, 1423-1423.	1.7	10
32	Loss of m6A Methyltransferase METTL5 Promotes Cardiac Hypertrophy Through Epitranscriptomic Control of SUZ12 Expression. Frontiers in Cardiovascular Medicine, 2022, 9, 852775.	2.4	10
33	Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment. ESC Heart Failure, 2022, 9, 2567-2575.	3.1	10
34	AVE 3085, a novel endothelial nitric oxide synthase enhancer, attenuates cardiac remodeling in mice through the Smad signaling pathway. Archives of Biochemistry and Biophysics, 2015, 570, 8-13.	3.0	9
35	Evaluation of the therapeutic effects of QuickOpt optimization in Chinese patients with chronic heart failure treated by cardiac resynchronization. Scientific Reports, 2018, 8, 4259.	3.3	8
36	Risk of Cardiovascular Mortality Associated With Serum Sodium and Chloride in the General Population. Canadian Journal of Cardiology, 2018, 34, 999-1003.	1.7	8

#	Article	IF	CITATIONS
37	CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. Cardiovascular Drugs and Therapy, 2020, 34, 763-772.	2.6	8
38	Effect of aggressive diuresis in acute heart failure with reduced and preserved ejection fraction. ESC Heart Failure, 2021, 8, 3248-3256.	3.1	8
39	Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy. Lipids in Health and Disease, 2019, 18, 32.	3.0	7
40	The role of angiopoietin-like protein 4 in phenylephrine-induced cardiomyocyte hypertrophy. Bioscience Reports, 2019, 39, .	2.4	7
41	Hispidulin Attenuates Cardiac Hypertrophy by Improving Mitochondrial Dysfunction. Frontiers in Cardiovascular Medicine, 2020, 7, 582890.	2.4	7
42	Weight Change and Mortality Risk in Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 681726.	2.4	7
43	Circle the Cardiac Remodeling With circRNAs. Frontiers in Cardiovascular Medicine, 2021, 8, 702586.	2.4	7
44	Cardiac CIP protein regulates dystrophic cardiomyopathy. Molecular Therapy, 2021, , .	8.2	7
45	Electrophysiological characteristics of the earliest activation site in idiopathic right ventricular outflow tract arrhythmias under miniâ€electrode mapping. Journal of Cardiovascular Electrophysiology, 2019, 30, 642-650.	1.7	6
46	Diastolic Reverse Dipping Pattern Is the Predictor for the Echocardiographic Changes in the Untreated Masked Hypertensive Patients. American Journal of Hypertension, 2019, 32, 588-596.	2.0	6
47	Association of household secondhand smoke exposure and mortality risk in patients with heart failure. BMC Cardiovascular Disorders, 2019, 19, 280.	1.7	6
48	Angiopoietin-Like Protein 7 and Short-Term Mortality in Acute Heart Failure. CardioRenal Medicine, 2020, 10, 116-124.	1.9	6
49	Major depression and clinical outcomes in patients with heart failure with preserved ejection fraction. European Journal of Clinical Investigation, 2021, 51, e13401.	3.4	6
50	Effects of Long-Term Statin Therapy in Coronary Artery Disease Patients with or without Chronic Kidney Disease. Disease Markers, 2015, 2015, 1-8.	1.3	5
51	Adenosine monophosphate-activated protein kinase attenuates cardiomyocyte hypertrophy through regulation of FOXO3a/MAFbx signaling pathway. Acta Biochimica Et Biophysica Sinica, 2016, 48, 827-832.	2.0	5
52	Nocturnal systolic hypertension is a risk factor for cardiac damage in the untreated masked hypertensive patients. Journal of Clinical Hypertension, 2019, 21, 1666-1674.	2.0	5
53	Association of physical activity and risk of atrial fibrillation in heart failure with preserved ejection fraction. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 247-253.	2.6	5
54	Association of Body-Weight Fluctuation With Outcomes in Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 689591.	2.4	5

#	Article	IF	CITATIONS
55	Association of Cyr61-cysteine-rich protein 61 and short-term mortality in patients with acute heart failure and coronary heart disease. Biomarkers in Medicine, 2019, 13, 1589-1597.	1.4	5
56	Role of N6-methyladenosine Modification in Cardiac Remodeling. Frontiers in Cardiovascular Medicine, 2022, 9, 774627.	2.4	5
57	First-in-human phase I results of APG-2449, a novel FAK and third-generation ALK/ ROS1 tyrosine kinase inhibitor (TKI), in patients (pts) with second-generation TKI-resistant ALK/ROS1 <sup>+</sup> non–small cell lung cancer (NSCLC) or mesothelioma Journal of Clinical Oncology, 2022, 40, 9071-9071.	1.6	5
58	Association of hyponatraemia and renal function in type 1 cardiorenal syndrome. European Journal of Clinical Investigation, 2020, 50, e13269.	3.4	4
59	Association of long-term SBP with clinical outcomes and quality of life in heart failure with preserved ejection fraction: an analysis of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Journal of Hypertension, 2021, 39, 1378-1385.	0.5	4
60	Prognostic Value of Cysteine-Rich Protein 61 Combined with N-Terminal Pro-B-Type Natriuretic Peptide for Mortality in Acute Heart Failure Patients with and without Chronic Kidney Disease. CardioRenal Medicine, 2020, 10, 11-21.	1.9	3
61	Efficacy and safety of xuezhikang once per day versus two times per day in patients with mild to moderate hypercholesterolaemia (APEX study): a protocol for a multicentre, prospective randomised controlled, open-label, non-inferiority study. BMJ Open, 2020, 10, e034585.	1.9	3
62	Effectiveness of Levoamlodipine Maleate for Hypertension Compared with Amlodipine Besylate: a Pragmatic Comparative Effectiveness Study. Cardiovascular Drugs and Therapy, 2021, 35, 41-50.	2.6	3
63	Ischemic risk in patients with heart failure with preserved ejection fraction: A post hoc analysis of the TOPCAT data. Atherosclerosis, 2022, 344, 1-6.	0.8	3
64	Thyroid hormones inhibit apoptosis of macrophage induced by oxidized lowâ€density lipoprotein. BioFactors, 2022, 48, 86-99.	5.4	3
65	Effect of Metoprolol Succinate in Patients with Stable Angina and Elevated Heart Rate Receiving Low-Dose Î <sup>2</sup> -Blocker Therapy. International Journal of Medical Sciences, 2017, 14, 477-483.	2.5	2
66	Sex-Specific Associations of Risks and Cardiac Structure and Function With Microalbumin/Creatinine Ratio in Diastolic Heart Failure. Frontiers in Cardiovascular Medicine, 2020, 7, 579400.	2.4	2
67	Clinical implication of pulmonary hospitalization in heart failure with preserved ejection fraction: from the TOPCAT. ESC Heart Failure, 2020, 7, 3801-3809.	3.1	2
68	Association between retinal arterial narrowing and left ventricular diastolic dysfunction in masked hypertensives. Journal of Clinical Hypertension, 2020, 22, 1050-1058.	2.0	2
69	Electrophysiological characteristics of epicardial to endocardial breakthrough in intractable cavotricuspid isthmusâ€dependent atrial flutter. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 462-471.	1.2	2
70	Associations of BMI with mortality in HFpEF patients with concomitant diabetes with insulin versus non-insulin treatment. Diabetes Research and Clinical Practice, 2022, 185, 109805.	2.8	2
71	Transplantation of a beating heart: A first in man. The Lancet Regional Health - Western Pacific, 2022, 23, 100449.	2.9	2
72	Subclinical endothelial dysfunction and low-grade inflammation play roles in the development of erectile dysfunction in young man with low risk of coronary heart disease. Heart, 2011, 97, A242-A242.	2.9	1

#	Article	IF	CITATIONS
73	Efficacy and tolerability of once-daily 160 mg valsartan in Chinese patients with mild to moderate hypertension. Experimental and Therapeutic Medicine, 2017, 13, 1109-1116.	1.8	1
74	Automatic annotation of local activation time was improved in idiopathic right ventricular outflow tract ventricular arrhythmia by novel electrogram "Lumipoint―algorithm. Journal of Interventional Cardiac Electrophysiology, 2021, 61, 79-85.	1.3	1
75	Cardiac hemodynamic response to the 6-minute walk test in patients with intestinal carcinoma undergoing bevacizumab treatment. Annals of Palliative Medicine, 2021, 10, 1362-1369.	1.2	1
76	Case Report: Area of Focus of Myocardial Infarction With Non-obstructive Coronary Arteries in Eosinophilic Granulomatosis With Polyangiitis. Frontiers in Cardiovascular Medicine, 2021, 8, 731897.	2.4	1
77	GW24-e1136â€Shear stress affects the uptake of oxidised low-density lipoprotein by human vascular endothelial cells. Heart, 2013, 99, A49.2-A49.	2.9	Ο
78	An electrographic AV optimization for the maximum integrative atrioventricular and ventricular resynchronization in CRT. BMC Cardiovascular Disorders, 2021, 21, 288.	1.7	0
79	Cardiac ISL1-Interacting Protein, a Cardioprotective Factor, Inhibits the Transition From Cardiac Hypertrophy to Heart Failure. Frontiers in Cardiovascular Medicine, 2022, 9, 857049.	2.4	0
80	Efficacy of INtensive Treatment vs. Standard Treatment of COmpound DanshEn Dripping Pills in Refractory Angina Patients With Incomplete Revascularization (INCODER Study): Study Protocol for a Multicenter, Double-Blind, Randomized Controlled, Superiority Trial. Frontiers in Cardiovascular Medicine, 2022, 9, 860059.	2.4	0